Cue Biopharma Hits New 52-Week High of $45.23, Up 2454%

Cue Biopharma, Inc. has reached a significant milestone by hitting a new 52-week high of USD 45.23 on July 10, 2026. This achievement marks a remarkable increase in the stock's performance, showcasing a staggering 2454.17% rise over the past year, significantly outpacing the S&P 500's performance of 20.62% during the same period. As a microcap company in the Pharmaceuticals & Biotechnology industry, Cue Biopharma has a market capitalization of USD 23 million. Despite its impressive stock performance, the company remains in a loss-making position, with a price-to-earnings ratio that is not applicable. The stock's price-to-book ratio stands at 0.88, indicating its valuation relative to its book value. The company's financial metrics also reveal a debt-to-equity ratio of -0.95 and a return on equity of -100.64%, reflecting its current financial structure. With a 52-week low of USD 4.97, the recent high underscores the stock's volatility and significant growth trajectory in the biotechnology sector.